Antibody Information

General Information of This Antibody
Antibody ID
ANI0QGUFO
Antibody Name
Anti-GPC1 mAb 01a033
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Glypican-1 (GPC1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
GPC-1 ADC 1 [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 21.71% (Day 24) Positive GPC1 expression (GPC1 +++/++)
Method Description
Antitumor efficacy of GPC1-ADC in HeLa (n = 6/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (1 mg/kg) was intravenously injected every four days for a total of 4 times.
In Vivo Model HeLa CDX model
In Vitro Model Endocervical adenocarcinoma HeLa cells CVCL_0030
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 28.13% (Day 32) Positive GPC1 expression (GPC1 +++/++)
Method Description
Antitumor efficacy of GPC1-ADC in ME180 (n = 7/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (1 mg/kg) was intravenously injected every four days for a total of 4 times.
In Vivo Model ME180 CDX model
In Vitro Model Cervical squamous cell carcinoma ME-180 cells CVCL_1401
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 33.65% (Day 32) Positive GPC1 expression (GPC1 +++/++)
Method Description
Antitumor efficacy of GPC1-ADC in ME180 (n = 7/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (3 mg/kg) was intravenously injected every four days for a total of 4 times.
In Vivo Model ME180 CDX model
In Vitro Model Cervical squamous cell carcinoma ME-180 cells CVCL_1401
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 43.94% (Day 24) Positive GPC1 expression (GPC1 +++/++)
Method Description
Antitumor efficacy of GPC1-ADC in HeLa (n = 6/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (3 mg/kg) was intravenously injected every four days for a total of 4 times.
In Vivo Model HeLa CDX model
In Vitro Model Endocervical adenocarcinoma HeLa cells CVCL_0030
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 69.65% (Day 24) Positive GPC1 expression (GPC1 +++/++)
Method Description
Antitumor efficacy of GPC1-ADC in HeLa (n = 6/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (10 mg/kg) was intravenously injected every four days for a total of 4 times.
In Vivo Model HeLa CDX model
In Vitro Model Endocervical adenocarcinoma HeLa cells CVCL_0030
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.49% (Day 32) Positive GPC1 expression (GPC1 +++/++)
Method Description
Antitumor efficacy of GPC1-ADC in ME180 (n = 7/group) xenograft models. When the mean tumor size of each cancer type reached approximately 130 mm3 , PBS, control-ADC or GPC1-ADC (10 mg/kg) was intravenously injected every four days for a total of 4 times.
In Vivo Model ME180 CDX model
In Vitro Model Cervical squamous cell carcinoma ME-180 cells CVCL_1401
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.04 nM
Positive GPC1 expression (GPC1 +++/++)
Method Description
HeLa, ME180, and RMG-1 cells were treated with anti-GPC1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h.
In Vitro Model Endocervical adenocarcinoma HeLa cells CVCL_0030
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.09 nM
Positive GPC1 expression (GPC1 +++/++)
Method Description
HeLa, ME180, and RMG-1 cells were treated with anti-GPC1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h.
In Vitro Model Cervical squamous cell carcinoma ME-180 cells CVCL_1401
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 100 nM Negative GPC1 expression (GPC1 -)
Method Description
HeLa, ME180, and RMG-1 cells were treated with anti-GPC1 monoclonal antibody (clone 01a033) or control IgG antibody for 144 h.
In Vitro Model Ovarian clear cell adenocarcinoma RMG-I cells CVCL_1662
References
Ref 1 Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int J Cancer. 2018 Mar 1;142(5):1056-1066. doi: 10.1002/ijc.31124. Epub 2017 Oct 31.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.